For adults with primary
immunodeficiency (PI)

ALYGLO™ is an immunoglobulin or "IG" replacement
therapy with an extra-purified formulation.1,2

Less sick time.

More you time.

By replacing missing antibodies, ALYGLO can help reduce sick time so you have more time for the things that make you shine.1

In a clinical study of 33 patients ages 17-70, people receiving ALYGLO experienced an average of only 0.03 acute serious bacterial infections, or "ASBIs," per patient year.1

Less contaminants.

More purity.

IG treatment is made from donated human blood plasma and contains certain immunoglobulins called IgG—a type of antibody that fights infection.3 All IG treatments are manufactured with the goal of providing pure IgG. However, other impurities that can cause side effects can remain in the treatment.2

It’s time to


ALYGLO is given through an IV, which is why it’s often called "IVIG."3

With 1 infusion every 3-4 weeks administered by a nurse either in your own home or at an infusion center, you will have support throughout your treatment journey.1

Did you know? All IVIGs are derived from donated human plasma, the liquid component of blood that contains antibodies.3 Each batch undergoes a rigorous purification process to help ensure the safety of the resulting treatment.3

But not all IVIGs are the same.

As a global manufacturer of plasma-derived treatments for more than 50 years, our mission is to improve the purity of IVIG with safety and tolerability in mind.

aClick here to see terms, conditions, and eligibility criteria.


  1. ALYGLO Prescribing Information. GC Biopharma; 2023.
  2. Kang GB, Huber A, Lee J, et al. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation. Front Cardiovasc Med. 2023;10:1253177.
  3. Immunoglobulin replacement therapy. Immune Deficiency Foundation. Accessed May 9, 2024. https://‌‌understanding-primary-immunodeficiency/‌treatment/‌immunoglobulin-replacement-therapy

ALYGLO™ is indicated for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

  • Thrombosis (blood clot formation) can happen with ALYGLO. Factors that increase this risk include advanced age, prolonged immobility, certain medical conditions, and cardiovascular risk factors.
  • ALYGLO may affect the kidneys. In some cases, it can lead to acute renal failure or death.
  • If you’re at risk for blood clots or kidney problems, your doctor should give you ALYGLO at the lowest effective dose and infusion rate. Staying well-hydrated before treatment is essential.
  • ALYGLO is not suitable for people who have had severe allergic reactions to immune globulin or those with IgA deficiency and a history of hypersensitivity.
  • If you experience any signs of hypersensitivity during the infusion, treatment should be stopped and epinephrine (an emergency medication) should be administered immediately.
  • ALYGLO may cause hyperproteinemia, increased serum viscosity, and hyponatremia (low sodium levels).
  • Aseptic Meningitis Syndrome (AMS) is a rare condition that can occur after receiving ALYGLO, especially with high doses or rapid infusion. Symptoms usually start within a few hours to 2 days after treatment. If AMS occurs, stopping ALYGLO usually leads to improvement within several days without lasting effects.
  • Hemolysis, a breakdown of red blood cells, may occur. Some patients may experience delayed hemolytic anemia due to increased sequestration of red blood cells. Severe hemolysis-related kidney dysfunction or disseminated intravascular coagulation has been reported.
  • Transfusion-Related Acute Lung Injury (TRALI) is a rare complication characterized by severe respiratory distress, pulmonary edema, and fever. Patients with TRALI may need oxygen therapy and ventilator support.
  • ALYGLO is made from human blood, which may carry a risk of transmitting infectious agents (such as viruses).
  • After receiving ALYGLO, some antibodies from the treatment may temporarily show up in blood tests. This could lead to misleading results, so your healthcare provider will consider this when interpreting lab results.
  • Common side effects include headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness.

For more information about ALYGLO, talk to your doctor and see the Product Information here.